

Structural basis of resistance of *Helicobacter pylori* DnaK to antimicrobial peptide pyrrolicorin

Musammat F. Nahar, and Anna Roujeinikova

Abstract—Bacterial molecular chaperone DnaK plays an essential role in protein folding, stress response and transmembrane targeting of proteins. DnaKs from many bacterial species, including *Escherichia coli*, *Salmonella typhimurium* and *Haemophilus influenzae* are the molecular targets for the insect-derived antimicrobial peptide pyrrolicorin. Pyrrolicorin-like peptides bind in the substrate recognition tunnel. Despite the high degree of cross-species sequence conservation in the substrate-binding tunnel, some bacteria are not sensitive to pyrrolicorin. This work addresses the molecular mechanism of resistance of *Helicobacter pylori* DnaK to pyrrolicorin. Homology modelling, structural and sequence analysis identify a single aminoacid substitution at the interface between the lid and the β -sandwich subdomains of the DnaK substrate-binding domain as the major determinant for its resistance.

Keywords—*Helicobacter pylori*, molecular chaperone DnaK, pyrrolicorin, structural biology.

I. INTRODUCTION

Helicobacter pylori is a gram-negative bacterium that colonises the stomachs of roughly 50% of the world's population[1] and is associated with numerous severe gastroduodenal diseases including gastric and duodenal ulcers, mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma[2, 3]. Eradication of *H. pylori* has been shown to reduce the recurrence of gastric cancer in patients who received endoscopic resection of early gastric cancer and the recurrence of both gastric and duodenal ulcers in patients with peptic ulcer disease[4, 5]. At present, there is no specific single drug that could effectively cure the *H. pylori* infection; current treatments involve the use of a combination of a proton pump inhibitor with two broad-spectrum antibiotics (mainly clarithromycin and either amoxicillin or metronidazole)[6]. An increasing prevalence of resistance to the antibiotic components of such regimens[7] requires development of drugs that specifically interact with *H. pylori*. The discovery that bacterial molecular chaperones DnaKs are the molecular targets for the insect-derived antimicrobial peptide pyrrolicorin (VDKGSYLPRPTPPRIYNNR)[8, 9] attracted interest to these enzymes as new targets for drug design. As a drug target, DnaK has not yet experienced

selective pressure in the clinical setting. Blocking DnaK activity inhibits the essential molecular chaperone function implicated in protein folding, stress response and transmembrane targeting of proteins (for the review on DnaK cellular functions, see [10]), thereby killing the bacteria. Non-toxicity to mammalian cells and good serum stability of pyrrolicorin-derived peptides make them promising drug candidates in treating emerging/re-emerging antimicrobial-resistant bacterial pathogens[9]. This highlights the importance of detailed structural characterization of inhibitor-protein interactions with a view to facilitating rational drug design.

We have recently established that pyrrolicorins target the substrate-binding tunnel of DnaK[11]. This site shows very little structural variation across different bacterial species. Nevertheless, both pyrrolicorin-sensitive and pyrrolicorin-resistant species have been identified. Native pyrrolicorin kills a broad range of bacterial species, including *E. coli*, *S. typhimurium*, *H. influenzae* and *Agrobacterium tumefaciens*. Species that are not sensitive to this peptide include *Helicobacter pylori*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes* and *Haemophilus ducreyi*[12]. This work addresses the molecular mechanism of resistance of *H. pylori* DnaK to pyrrolicorin. The high level of sequence identity (approximately 60%) between *H. pylori* and *E. coli* DnaK substrate binding domains allowed us to build an accurate homology model for the *H. pylori* protein, based on the known 3D coordinates of its *E. coli* counterpart[11], and pinpoint the single aminoacid substitution that confers resistance.

II. MATERIALS AND METHODS

The homology model of *H. pylori* DnaK SBD was constructed using MODELLER (9v7)[13, 14] based on the coordinates of the 2.1-Å resolution crystallographic model of the complex of *E. coli* DnaK SBD with pyrrolicorin (PDB RSCB 3DPO)[11]. The spatial restraints, including distance restraints and torsion angle restraints, were derived from the sequence alignment and used in the automated 3D-model construction of the protein. The model was further optimized with the internal optimizer of MODELLER. Model quality was assessed using the Prosa2003 [15, 16], ProQ[17] and Verify3D[18] quality scores.

M. N. and A. R. (the corresponding author) are with the Department of Microbiology, Building 76, Monash University, Clayton Campus, Victoria 3800, Australia (phone: +61 399029194; fax +61 399029222; e-mail: Anna.Roujeinikova@med.monash.edu.au).

Multiple sequence alignment was performed with ClustalW2 using the default parameters. Structural superimpositions were carried out using the Swiss PDB viewer[19]. Figures were prepared using PYMOL[20].

III. RESULTS AND DISCUSSION

DnaKs from different bacteria have a strictly conserved structural feature proven to be indispensable for their function: a 'latch' between the lid and the β -sandwich subdomains formed by residues Asp431, Arg467, Asp540, His544 and Lys548 (*E. coli* numbering) [21] (Fig. 1).




Fig. 1 The functionally important network of hydrogen bonds and ion pairs (called the 'latch') at the interface between the lid and the β -sandwich subdomains [21].

Analysis of the crystal structure of the *E. coli* DnaK substrate-binding domain (SBD) in complex with a pyrrolic acid-derived peptide inhibitor[11] reveals that this peptide acts as a site-specific, dual mode (competitive and allosteric) inhibitor. The competitive inhibition mode is demonstrated by the fact that it occupies the conventional substrate-binding tunnel of SBD (Fig. 2), mimicking the natural substrate. The detailed comparative analysis of the protein-ligand contacts in the peptide inhibitor complex and in the complex with the non-inhibiting peptide suggests that the allosteric effect of pyrrolic acid is due to the introduction of a bulky aliphatic cyclohexylalanine (*Z*) side chain at the position of Leu3 in the non-inhibiting peptide, which causes disruption of the 'latch' between the β -sandwich and the lid subdomains (Fig. 3). Disruption of the 'latch' by other means (e.g. site-directed mutagenesis) renders DnaK inactive. The pyrrolic acid binding is therefore likely to affect the refolding DnaK activity in a similar way. The structural basis behind

this phenomenon is as follows: introduction of a bulky aliphatic side chain of cyclohexylalanine (*Cha*) at the position of Leu in the non-inhibiting peptide induces a conformational rearrangement in the protein that creates a more hydrophobic environment for this large apolar group at a cost of breaking several hydrogen bonds[11] (Fig. 3).




Fig. 2 The pyrrolic acid binding site of *E. coli* DnaK. The peptide inhibitor is drawn in a stick representation with carbons in black. The molecular surface of DnaK is shown, and the positions of the residues that form the inhibitor binding site are highlighted in red.

In order to gain an understanding of why pyrrolic acid inhibits *E. coli* DnaK but not the *H. pylori* chaperone, we created a 3D homology model of the complex of *H. pylori* DnaK with pyrrolic acid-like peptide using the coordinates of the crystal structure of the complex of *E. coli* DnaK SBD with a pyrrolic acid-derived peptide[11]. The peptide was excluded from the initial calculations for the protein moiety. To model the peptide binding in the substrate-binding tunnel of *H. pylori* DnaK, the 3D atomic model of the latter was superimposed with the crystal structure of the *E. coli* DnaK SBD complex with the inhibitor peptide. The conformations of the side chains in the *H. pylori* protein model around the binding cavity were manually adjusted to remove clashes with the peptide atoms using the manipulation tools implemented in Coot[22]. This model was further optimised by structure idealization through iterative manual model re-building and simulated annealing calculations using an approach similar to that previously employed by Roujeinikova for modelling of the peptidoglycan binding by the motor protein B[23]. The detailed comparative analysis of the generated model and the crystal structure of the inhibitor complex of *E. coli* DnaK SBD shows that the residues forming the substrate binding tunnel are highly conserved between the two proteins. In contrast, the 'latch' at the interface between the lid and the β -sandwich subdomains shows different residue composition.




Fig. 3 Superposition of the pyrrolicin (carbons in black) and the NR peptide bound to SBD in their respective complexes, showing the broken latch and the additional hydrophobic contacts stabilizing cyclohexylalanine (Z).




Fig. 4 Superimposition of the crystal structure of the *E. coli* DnaK complex with a pyrrolicin-derived peptide with the homology model of *H. pylori* DnaK. The inhibitor peptide is drawn in all-atom representation. The side chains of His541 (*E. coli* DnaK) and Ser535 (*H. pylori* DnaK) are shown.

<i>E. coli</i>	KMVRDAEANAEDRKFEELVQTRNQGDLHSTRK	548	pyrrolicin-sensitive
<i>Klebsiella pneumoniae</i>	KMVRDAEANAESDRKFEELVQTRNQGDLHSTRK	548	
<i>Salmonella typhimurium</i>	KMVRDAEANAESDRKFEELVQTRNQGDLHSTRK	548	
<i>Micrococcus luteus</i>	RMVKDAEAHADEDRKRREAADRRNQAEQ\$AYSVDK	525	
<i>H. pylori</i>	KMVKDAELHKEEDAKKKEVIEARNHADS LAHQ\$TQK	542	pyrrolicin-resistant
<i>Haemophilus influenzae</i>	QMVRDAEANADADRKFEELVQARNQADGLAHATRK	547	
<i>Pseudomonas aeruginosa</i>	QMVRDAEANAEDRKFEELAAARNQGLALVHATRK	548	
<i>Staphylococcus aureus</i>	RMVKDAEVNAEADKKRREEVDLRNEADSLVFQVEK	518	

Fig. 5 Sequence comparison of the region surrounding the residue His541 in *E. coli* DnaK with other known DnaKs. Highlighted are the residues at positions equivalent to His541 in the *E. coli* protein.

The structure superimposition reveals that the Ser535 residue of *H. pylori* protein occupies a position that is structurally equivalent to position 541 (histidine) in the *E. coli* protein (Fig. 4). Our previous analysis suggests that the interactions between His541 and the inhibitor drive the conformational change that breaks the 'latch' and renders the chaperone inactive. The side chain of His541 shields the large apolar side chain of cyclohexylalanine from the solvent in the inhibitor complex of *E. coli* DnaK – the function that the smaller side chain of serine would not be able to perform. Sequence

alignment of DnaKs from pyrrolicin-sensitive and pyrrolicin-resistant bacteria reveals that the former have a large side chain (histidine or glutamine) at the position equivalent to 541 of *E. coli* DnaK, whereas the latter have a small side chain (glycine, alanine or serine) at this position (Fig. 5). Our analysis therefore suggests that the presence of a serine residue at position 535 of *H. pylori* DnaK is the major determinant for its resistance to pyrrolicin. Our efforts are currently being directed towards testing this hypothesis using site-directed mutagenesis.

ACKNOWLEDGMENT

This work was supported by grants from the Wellcome Trust and the Australian Research Council to AR. AR is a Research Fellow of the Australian Research Council.

REFERENCES

- [1] A. Covacci, J. L. Telford, G. Del Giudice *et al.*, "Helicobacter pylori virulence and genetic geography," *Science*, vol. 284, no. 5418, pp. 1328-33, May 21, 1999.
- [2] B. J. Marshall, and J. R. Warren, "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration," *Lancet*, vol. 1, no. 8390, pp. 1311-5, Jun 16, 1984.
- [3] R. M. Peek, Jr., and M. J. Blaser, "Helicobacter pylori and gastrointestinal tract adenocarcinomas," *Nat Rev Cancer*, vol. 2, no. 1, pp. 28-37, Jan, 2002.
- [4] A. C. Ford, B. C. Delaney, D. Forman *et al.*, "Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients," *Cochrane Database Syst Rev*, no. 2, pp. CD003840, 2006.
- [5] N. Uemura, T. Mukai, S. Okamoto *et al.*, "Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer," *Cancer Epidemiol Biomarkers Prev*, vol. 6, no. 8, pp. 639-42, Aug, 1997.
- [6] G. Treiber, S. Ammon, E. Schneider *et al.*, "Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication," *Helicobacter*, vol. 3, no. 1, pp. 54-8, Mar, 1998.
- [7] N. Broutet, S. Tchamgoue, E. Pereira *et al.*, "Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients," *Aliment Pharmacol Ther*, vol. 17, no. 1, pp. 99-109, Jan, 2003.
- [8] G. Kragol, S. Lovas, G. Varadi *et al.*, "The antibacterial peptide pyrrolicorin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding," *Biochemistry*, vol. 40, no. 10, pp. 3016-26, Mar 13, 2001.
- [9] L. Otvos, Jr., K. Bokonyi, I. Varga *et al.*, "Insect peptides with improved protease-resistance protect mice against bacterial infection," *Protein Sci*, vol. 9, no. 4, pp. 742-9, Apr, 2000.
- [10] M. P. Mayer, and B. Bukau, "Hsp70 chaperones: cellular functions and molecular mechanism," *Cell Mol Life Sci*, vol. 62, no. 6, pp. 670-84, Mar, 2005.
- [11] M. Liebscher, and A. Roujeinikova, "Allosteric coupling between the lid and interdomain linker in DnaK revealed by inhibitor binding studies," *J Bacteriol*, vol. 191, no. 5, pp. 1456-62, Mar, 2009.
- [12] G. Kragol, R. Hoffmann, M. A. Chattergoon *et al.*, "Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrolicorin," *Eur J Biochem*, vol. 269, no. 17, pp. 4226-37, Sep, 2002.
- [13] A. Sali, and T. L. Blundell, "Comparative protein modelling by satisfaction of spatial restraints," *J Mol Biol*, vol. 234, no. 3, pp. 779-815, Dec 5, 1993.
- [14] A. Fiser, R. K. Do, and A. Sali, "Modeling of loops in protein structures," *Protein Sci*, vol. 9, no. 9, pp. 1753-73, Sep, 2000.
- [15] M. J. Sippl, "Recognition of errors in three-dimensional structures of proteins," *Proteins*, vol. 17, no. 4, pp. 355-62, Dec, 1993.
- [16] M. Wiederstein, and M. J. Sippl, "ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins," *Nucleic Acids Res*, vol. 35, no. Web Server issue, pp. W407-10, Jul, 2007.
- [17] B. Wallner, and A. Elofsson, "Can correct protein models be identified?," *Protein Sci*, vol. 12, no. 5, pp. 1073-86, May, 2003.
- [18] J. U. Bowie, R. Luthy, and D. Eisenberg, "A method to identify protein sequences that fold into a known three-dimensional structure," *Science*, vol. 253, no. 5016, pp. 164-70, Jul 12, 1991.
- [19] N. Guex, and M. C. Peitsch, "SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling," *Electrophoresis*, vol. 18, no. 15, pp. 2714-23, Dec, 1997.
- [20] W. L. DeLano, "The PyMOL Molecular Graphics System: Version 0.90 (DeLano Scientific, Palo Alto, CA)," 2003.
- [21] X. Zhu, X. Zhao, W. F. Burkholder *et al.*, "Structural analysis of substrate binding by the molecular chaperone DnaK," *Science*, vol. 272, no. 5268, pp. 1606-14, Jun 14, 1996.
- [22] P. Emsley, and K. Cowtan, "Coot: model-building tools for molecular graphics," *Acta Crystallogr D Biol Crystallogr*, vol. 60, no. Pt 12 Pt 1, pp. 2126-32, Dec, 2004.
- [23] A. Roujeinikova, "Crystal structure of the cell wall anchor domain of MotB, a stator component of the bacterial flagellar motor: implications for peptidoglycan recognition," *Proc Natl Acad Sci U S A*, vol. 105, no. 30, pp. 10348-53, Jul 29, 2008.